首页|补肾生精方对少弱精子症潜在防治作用的研究进展

补肾生精方对少弱精子症潜在防治作用的研究进展

Research Progress on the Potential Therapeutic Effect of Bushen Shengjing Prescription on Oligoasthenozoospermia

扫码查看
目的 探讨补肾生精方(BSP)治疗少弱精子症(OA)的潜在防治作用,为后续研究提供理论参考.方法 通过文献回顾,分析BSP中八味中药的药理作用及其在OA治疗中的协同效应.结合已有研究数据,评估BSP对改善精子质量的效果.结果 BSP在治疗OA中显示出良好疗效,可能通过抗氧化、抗炎、抗凋亡等多途径改善精子质量.临床研究初步表明,BSP能够显著提高OA患者的精子活力和数量,从而提高生育能力.结论 BSP在治疗OA方面具有显著的治疗潜力,其多成分、多靶点的作用机制为OA的治疗提供了新的治疗策略.下一步研究应继续验证井深入研究BSP的疗效及作用机制,以促进其在临床上的广泛应用.
Objective To explore the potential therapeutic effects of Bushen Shengjing prescription(BSP)on oligoasthenozoospermia(OA),providing theoretical references for subsequent research.Methods The pharmacological effects of the eight Chinese medicinal herbs in BSP and their synergistic effects in the treatment of OA were analyzed through literature review.The effect of BSP on improving sperm quality was evaluated combined with existing research data.Results BSP has shown good efficacy in the treatment of OA,possibly improving sperm quality through multiple pathways such as antioxidation,anti-inflammation,and anti-apoptosis.Preliminary clinical studies have indicated that BSP can significantly increase the sperm vitality and quantity of OA patients,thereby improving fertility.Conclusion BSP has significant therapeutic potential in the treatment of OA,and its multi-component,multi-target mechanism of action provides a new treatment strategy for OA.Future research should further verify and study the efficacy and mechanism of action of BSP to promote its widespread clinical application.

Bushen Shengjing PrescriptionOligoasthenozoospermiaResearch ProgressSperm QualitySperm VitalitySperm CountMale InfertilityTraditional Chinese Medicine

白雪、陈亚飞、唐田、刘柘君、谭天阳、刘振权

展开 >

中国中医科学院医学实验中心,北京市中医药防治重大疾病基础研究重点实验室,北京 100700

北京中医药大学中药学院,北京 102488

中国中医科学院中医临床基础医学研究所,北京 100007

中国科学院北京基因组研究所,北京 100101

首都医科大学中医药学院,北京 100069

中国中医科学院西苑医院康复医学科,北京 100091

展开 >

补肾生精方 少弱精子症 进展 精子质量 精子活力 精子数量 男性不育 中药

2024

中国药物警戒
国家药品监督管理局药品评价中心(国家药品不良反应监测中心)

中国药物警戒

CSTPCD
影响因子:1.105
ISSN:1672-8629
年,卷(期):2024.21(11)